[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0509182A - co-cristais de gossipol e uso dos mesmos - Google Patents

co-cristais de gossipol e uso dos mesmos

Info

Publication number
BRPI0509182A
BRPI0509182A BRPI0509182-9A BRPI0509182A BRPI0509182A BR PI0509182 A BRPI0509182 A BR PI0509182A BR PI0509182 A BRPI0509182 A BR PI0509182A BR PI0509182 A BRPI0509182 A BR PI0509182A
Authority
BR
Brazil
Prior art keywords
crystals
gossypol
relates
carboxylic acid
acid
Prior art date
Application number
BRPI0509182-9A
Other languages
English (en)
Inventor
Shaomeng Wang
Dajon Yang
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of BRPI0509182A publication Critical patent/BRPI0509182A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

CO-CRISTAIS DE GOSSIPOT E USO DOS MESMOS Esta invenção se refere a composições compreendendo co-cristais de (-)- gossipol com um ácido carboxílico de C~ 1-8~ ou um ácido sulfânico de C~ 1-8~ que são úteis como inibidores das proteínas da família Bcl-2. A invenção também se refere ao uso de co-cristais de (-)-gossipol com um ácido carboxílico de C~ 1-8~ ou um ácido sulfónico de C~ 1-8~ para induzir apoptose em células e para sensibilizar células à indução de morte celular apoptótica.
BRPI0509182-9A 2004-03-25 2005-03-24 co-cristais de gossipol e uso dos mesmos BRPI0509182A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55624904P 2004-03-25 2004-03-25
PCT/US2005/009673 WO2005094804A1 (en) 2004-03-25 2005-03-24 Gossypol co-crystals and the use thereof

Publications (1)

Publication Number Publication Date
BRPI0509182A true BRPI0509182A (pt) 2007-09-18

Family

ID=35063489

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509182-9A BRPI0509182A (pt) 2004-03-25 2005-03-24 co-cristais de gossipol e uso dos mesmos

Country Status (15)

Country Link
US (3) US7342046B2 (pt)
EP (1) EP1732529A4 (pt)
JP (1) JP2007530568A (pt)
KR (2) KR20080097496A (pt)
CN (1) CN1960719B (pt)
AU (2) AU2005228998B2 (pt)
BR (1) BRPI0509182A (pt)
CA (1) CA2561303C (pt)
EA (1) EA011218B1 (pt)
IL (1) IL178286A0 (pt)
MX (1) MXPA06010938A (pt)
NO (1) NO20064829L (pt)
SG (1) SG151299A1 (pt)
WO (1) WO2005094804A1 (pt)
ZA (1) ZA200607956B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
KR20050098249A (ko) * 2003-01-17 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 양성 전립선 비대증의 치료방법
EA011218B1 (ru) * 2004-03-25 2009-02-27 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Сокристаллы госсипола и их применение
WO2008150506A1 (en) * 2007-05-31 2008-12-11 Ascenta Therapeutics, Inc. Pulsatile dosing of gossypol for treatment of disease
KR20100065190A (ko) 2007-09-14 2010-06-15 닛토덴코 가부시키가이샤 약물 담체
US7696372B2 (en) * 2007-10-01 2010-04-13 Ascenta Therapeutics, Inc. Process for preparing R-gossypol L-phenylalaninol dienamine
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
KR101604566B1 (ko) 2007-12-28 2016-03-17 가부시키가이샤 브리지스톤 히드록시아릴 관능화 중합체
WO2010019914A2 (en) * 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
KR101738709B1 (ko) 2009-06-30 2017-05-22 가부시키가이샤 브리지스톤 히드록실기 함유 디페닐에틸렌으로 관능화된 중합체
JP5889787B2 (ja) * 2009-07-01 2016-03-22 株式会社ブリヂストン フリーラジカル開始重合によるヒドロキシアリール官能化共重合体の製造方法
CN101810577B (zh) * 2010-05-06 2011-09-07 山东大学 治疗肿瘤的棉酚静脉注射脂肪乳剂
WO2011153109A2 (en) 2010-05-31 2011-12-08 Bridgestone Corporation Hydroxyl group-containing methylstyrene and polymers incorporating same
KR101408370B1 (ko) * 2012-06-26 2014-06-18 주식회사지씨비 아리피프라졸-유기산 공결정을 함유하는 제제 및 이의 제조 방법
KR101579371B1 (ko) * 2014-02-27 2015-12-22 국립암센터 고시폴 및 펜포르민을 유효성분으로 함유하는 암 치료용 약제학적 조성물
CN108697667A (zh) 2016-02-18 2018-10-23 延世大学校产学协力团 用于治疗癌症、含有多酚化合物作为活性成分的药物组合物
CN110312508A (zh) * 2017-02-22 2019-10-08 国立癌研究院 含有棉酚和苯乙双胍作为活性成分的预防和治疗胰腺癌的药物组合物
CN110545805A (zh) * 2017-04-22 2019-12-06 秦才东 一种抑制细胞糖酵解过程的方法及应用
KR102259892B1 (ko) * 2019-08-05 2021-06-04 주식회사 하임바이오 식물유래 폴리페놀염의 대량 제조 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3364242A (en) 1963-07-05 1968-01-16 Swift & Co Separation of gossypol from cottonseed oil
US3347885A (en) 1966-01-03 1967-10-17 Anderson Clayton & Co Inc Cottonseed oil direct extraction method
US3647791A (en) 1967-09-19 1972-03-07 Ciba Geigy Corp 2 3 4 4a 5 6-hexahydro - 1h - pyrazino (1 2-a) quinolines and pharmaceutical compositions containing same
DE1917341C3 (de) 1969-04-03 1973-10-18 Wsesojusnyj Nautschno-Issledowatelskij Institut Schirow, Leningrad (Sowjetunion) Verfahren zur Gewinnung von Baum wollsaatol
SU322042A1 (ru) 1969-07-15 1976-02-15 Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср Способ очистки госсипола
NL7303876A (pt) 1972-03-30 1973-10-02
US4297341A (en) 1980-05-09 1981-10-27 University Of Illinois Foundation Spermicidal composition
SU1351915A1 (ru) 1982-06-16 1987-11-15 Институт Биоорганической Химии Ан Узсср Способ получени госсипола из антранилата госсипола
US4747979A (en) 1984-07-02 1988-05-31 The Dow Chemical Company Removal of toxins from cottonseed
US4806568A (en) 1985-09-12 1989-02-21 Research Corporation Gossypol derivatives
US5260327A (en) 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
JPH01132542A (ja) 1987-11-19 1989-05-25 Toomen:Kk ゴッシポールラセミ体の光学分割法
CN1017705B (zh) 1987-12-26 1992-08-05 中国医学科学院药物研究所 制备光学活性棉酚的方法
CH676360A5 (en) 1988-12-28 1991-01-15 Inst Bioorg Khim Nauk Uzbexkoi Purificn. of antiviral gossypol cpd. - by recrystallisation from ether with hexane
US5059717A (en) 1989-01-05 1991-10-22 Ibragimov Bakhtiyar T Method for purification of 2,2'-di(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-naphthaldehyde)
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
CN1044455A (zh) 1989-01-25 1990-08-08 乌兹别克苏维埃共和国科学院生物有机化学研究所 2，2，-二(1，6，7-三羟基-3-甲基-5-异丙基-8-萘甲醛)的纯化方法
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5277909A (en) 1990-08-24 1994-01-11 The United States Of America, As Represented By The Secretary Of Agriculture Method for removal of gossypol from cottonseed meal by the use of urea in a borate containing buffer
US5077441A (en) 1990-10-05 1991-12-31 The United States Of America As Represented By The Secretary Of Agriculture Selective gossypol abatement process from oil extraction of cottonseed
US5112637A (en) 1990-11-05 1992-05-12 The United States Of America As Represented By The Secretary Of Agriculture Extraction of gossypol from cottonseed
RU2067111C1 (ru) 1992-06-16 1996-09-27 Узбекский научно-исследовательский институт химической технологии катализа им.А.Султанова Способ получения госсипола из сырого черного хлопкового масла
PT651636E (pt) 1992-07-24 2003-02-28 Univ Johns Hopkins Quimioterapia contra o cancro
SK106395A3 (en) 1993-03-01 1995-12-06 Merck Sharp & Dohme Treating and treatment or prevention of mental diseases
CN1094392A (zh) 1993-04-20 1994-11-02 徐世江 碱液提取棉酚法
NZ284851A (en) 1994-08-05 1998-07-28 Pfizer 1-[3-(piperazin-1-yl)-prop-1-yl] benzimidazole derivatives and their use in the treatment of cns disorders
US6094217A (en) * 1994-10-27 2000-07-25 Fuji Photo Film Co., Ltd. Automatic regenerating method for film image
US5780675A (en) 1995-04-28 1998-07-14 The University Of New Mexico Deoxygossylic compounds
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
EP0951028B8 (en) * 1996-08-31 2003-08-06 Toyo Denso Kabushiki Kaisha Engine igniting coil device
AU1289899A (en) 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6113397A (en) * 1999-02-10 2000-09-05 General Instrument Corporation Coaxial connectors mounted back-to-back on backplane
AU2002239258A1 (en) 2000-11-17 2002-06-03 Jingson Wang Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon
JP2005502579A (ja) * 2000-12-15 2005-01-27 ワックヴォム リミテッド 新生血管形成に関連する状態を処置するための方法および組成物
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
NZ529792A (en) * 2001-05-30 2007-04-27 Univ Michigan Small molecule antagonists of Bcl-2 family proteins
CA2450370A1 (en) 2001-06-11 2002-12-19 Jody Mesaros Accelerators for increasing the rate of formation of free radicals and reactive oxygen species
US20030119894A1 (en) 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
CN1229321C (zh) 2001-09-06 2005-11-30 新疆科赛生物工程有限公司 用二苯胺棉酚生产棉酚的方法
PL1653943T6 (pl) 2003-06-25 2009-02-27 The Burnham Inst La Jolla Pochodne katecholu do leczenia raka
EA011218B1 (ru) * 2004-03-25 2009-02-27 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Сокристаллы госсипола и их применение

Also Published As

Publication number Publication date
MXPA06010938A (es) 2007-01-25
SG151299A1 (en) 2009-04-30
CN1960719A (zh) 2007-05-09
US7432300B2 (en) 2008-10-07
ZA200607956B (en) 2008-02-27
IL178286A0 (en) 2007-03-08
KR20070026473A (ko) 2007-03-08
US20090082445A1 (en) 2009-03-26
EA011218B1 (ru) 2009-02-27
JP2007530568A (ja) 2007-11-01
US20050234135A1 (en) 2005-10-20
WO2005094804A1 (en) 2005-10-13
NO20064829L (no) 2006-12-20
KR100906843B1 (ko) 2009-07-08
US20070293585A1 (en) 2007-12-20
EP1732529A1 (en) 2006-12-20
AU2005228998A1 (en) 2005-10-13
EA200601562A1 (ru) 2007-02-27
KR20080097496A (ko) 2008-11-05
CN1960719B (zh) 2011-12-07
US7342046B2 (en) 2008-03-11
CA2561303C (en) 2011-01-18
AU2009200387A1 (en) 2009-02-19
AU2005228998B2 (en) 2008-11-06
EP1732529A4 (en) 2009-02-25
CA2561303A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
BRPI0509182A (pt) co-cristais de gossipol e uso dos mesmos
BRPI0810522B8 (pt) compostos miméticos diazo bicíclicos de smac, composição farmacêutica e kit compreendendo ditos compostos e uso dos mesmos para o tratamento de câncer
BRPI0819714A8 (pt) Formulações de proteína e métodos de produção das mesmas
ECSP11011297A (es) Proteinas ligadoras il-17
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
BRPI0514504A (pt) pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
CL2012002415A1 (es) Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.
BR112015027377A8 (pt) Compostos oligoméricos com grupos de conjugado, composições compreendendo os referidos compostos e usos dos mesmos
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BRPI0922350A2 (pt) anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra.
ECSP088758A (es) Métodos para reducir la aglomeración de proteína
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112015008708A2 (pt) composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma
NO20085074L (no) Toverdige SMAC-mimetika og anvendelsene derav
NI201000079A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrófilos.
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BRPI0506883A (pt) miméticos de smac conformacionalmente comprimidos e seus usos
MX2008006589A (es) Composiciones de edulcorante natural de mesa, de alta potencia, con perfil temporal y/o de sabor mejorado, metodos para su formulacion, y usos
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
CL2011002765A1 (es) Anticuerpo anti-factor de crecimiento nervioso (ngf) con estabilidad in vivo aumentada; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; kit; y su uso para tratar una enfermedad o afeccion relacionada con ngf.
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
BR112015020235A2 (pt) fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2507 DE 22-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.